NCT05758389

Tislelizumab Combined APF Chemotherapy in the Treatment of Locally Advanced Head and Neck Tumors

A Prospective Single-center, Single-arm Clinical Study of the PD-1 Inhibitor Tislelizumab Combined With APF Sequential Surgery or Radical Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Head and Neck Tumors

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 29 (estimated)
• Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to test in describe participant population. The main questions it aims to answer are: 1. evaluate the efficacy and safety of tislelizumab combined with APF sequential surgery or radical concurrent chemoradiotherapy in the treatment of locally advanced head and neck tumors. 2. the exploration of efficacy-related immune microenvironment genes Participants will receive tislelizumab combined with APF sequential surgery or radical concurrent chemoradiotherapy.

Conditions

• Head and Neck Tumors

Interventions

Type	Name	Description
DRUG	Tislelizumab, Paclitaxel (albumin-bound type), Cisplatin, 5-FU	evaluate the efficacy and safety of immunotherapy combined with chemotherapy

Timeline

• Start date: 2022-04-01
• Primary completion: 2025-08-07
• Completion: 2025-12-07
• First posted: 2023-03-07
• Last updated: 2025-09-05

Locations

1 site across 1 country: China